The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,516,207 in first-year total cost, median $238,716.
Most frequent study sections
- Special Emphasis Panel[ZRG1 DKUS-N (10)]2
- Special Emphasis Panel[ZRG1 DKUS-L (11)]1
- Special Emphasis Panel[ZRG1 EMNR-S (10)]1
- Special Emphasis Panel[ZRG1 EMNR-W (10)]1
- Special Emphasis Panel[ZRG1 IMST-L (11)]1
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC1
- IATERION, INC.1
- L2 DIAGNOSTICS, LLC1
- METABOLIC SOLUTIONS DEVELOPMENT CO1
- VISIONARY PHARMACEUTICALS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Estrogen Receptor Coligand Reprogramming of Menopausal Hormone Therapy1R43DK109862-01 | LEITMAN, DALE C | IATERION, INC., CA | $180,129 | ZRG1 |
| 2016 | Identification of RORg drug candidates for the treatment of NASH1R43DK111290-01 | ZAPF, JIM | VISIONARY PHARMACEUTICALS, INC., CA | $143,482 | ZRG1 |
| 2015 | Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease1R43DK105694-01 | WROBEL, JAY EDWARD | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2015 | Therapeutic Inhibition of MIF in Type 1 Diabetes1R43DK104522-01 | ANTHONY, KAREN G.USMANI-BROWN, SAHAR | L2 DIAGNOSTICS, LLC, CT | $297,302 | ZRG1 |
| 2014 | Pre-Clinical Development of Topical Pirenzepine for Treating Diabetic Neuropathy1R44DK104512-01 | HANSEN, ANGELA | WINSANTOR, INC., CA | $473,338 | ZRG1 |
| 2014 | Therapeutic Use of mTOT Modulators in Polycystic Kidney Disease1R43DK104508-01 | COLCA, JERRY RAYMONDKLETZIEN, ROLF F | METABOLIC SOLUTIONS DEVELOPMENT CO, MI | $121,956 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.